• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Calixar, U of Avignon to launch new research lab for target discovery

Calixar, U of Avignon to launch new research lab for target discovery

June 28, 2016
CenterWatch Staff

Calixar, a French biotech company specialized in the native isolation of membrane therapeutic targets/antigens, and the French University of Avignon, Bio-organic Chemistry and Amphiphilic Systems Team (CBSA), has launched the CHEM2STAB Laboratory (CHEMistry for STABilization) supported by the French National Research Agency (ANR). 

CHEM2STAB is a unique laboratory in the world gathering high-level competencies in chemistry, physical chemistry, biochemistry and structural biology. The main objective of this laboratory is the development of new chemical molecules able to extract and stabilize membrane therapeutic targets without denaturation, and also promoting their crystallization. The discovery of new membrane therapeutic targets is a booming sector implying major challenges in human and animal health. 

“Recent socio-economic studies have highlighted the lack of innovation in the pharmaceutical industry, especially in the discovery field. In particular, there is a growing need in the development of new physicochemical processes allowing the structural and functional preservation of complex therapeutic targets. This crucial aspect implemented by CHEM2STAB will have a significant impact on the quality and performance of future drugs and vaccines,” said Emmanuel Dejean, CEO of Calixar and co-founder of CHEM2STAB. 

“CHEM2STAB will allow us to considerably increase the scientific and economical value of the work conducted at Avignon University. The initiative is aligned with the common objective of gathering private and academic research to facilitate the creation and validation of new chemical compounds with high potential for native membrane protein isolation,” said Grégory Durand, Professor at Avignon University, CBSA Team Manager and Co-founder of CHEM2STAB. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing